Cargando…

Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies

We report here the results of a phase 3 study to assess the efficacy, safety, and tolerability of GC5107, a new 10% liquid intravenous immunoglobulin (IVIG) in preventing serious bacterial infections in patients with primary immunodeficiency (ClinicalTrials.gov: NCT02783482). Over a 12-month study p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perez, Elena E., Hébert, Jacques, Ellis, Anne K., Alpan, Oral, Lumry, William R., Shapiro, Ralph, Suez, Daniel, Mandujano, J. Fernando, Wasserman, Richard L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297997/ https://www.ncbi.nlm.nih.gov/pubmed/34305948 http://dx.doi.org/10.3389/fimmu.2021.707463

Ejemplares similares

Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2012)

Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies
por: Kobayashi, Roger H., et al.
Publicado: (2019)

Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig(®)]) in the treatment of patients with primary immunodeficiencies
por: Kobayashi, Roger H., et al.
Publicado: (2022)

Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease
por: Wasserman, Richard L., et al.
Publicado: (2016)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
por: Scheuerlein, Philipp, et al.
Publicado: (2018)

P1505: TOLERABILITY AND SAFETY OF INTRAVENOUS IMMUNOGLOBULINS (5% AND 10%) FOR THE TREATMENT OF PATIENTS WITH SECONDARY IMMUNODEFICIENCIES – FINAL SUBGROUP RESULTS OF A NON-INTERVENTIONAL SAFETY STUDY
por: Habier, Angela, et al.
Publicado: (2023)

Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig(®)) in the treatment of patients with primary immunodeficiencies
por: Kobayashi, Roger H, et al.
Publicado: (2022)

A clinician’s guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases
por: Epland, Kristin, et al.
Publicado: (2022)

Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin
por: Ahmed, A. Razzaque, et al.
Publicado: (2018)

Surveillance study on the tolerability and safety of Flebogamma(®) DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients
por: Alsina, Laia, et al.
Publicado: (2017)

Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex(®) 10% Versus Gammaplex(®) 5% in Subjects with Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2017)

Neonatal sepsis and transient immunodeficiency: Potential for novel immunoglobulin therapies?
por: Beudeker, Coco R., et al.
Publicado: (2022)

Low rates of headache and migraine associated with intravenous immunoglobulin infusion using a 15-minute rate escalation protocol in 123 patients with primary immunodeficiency
por: Geng, Bob, et al.
Publicado: (2023)

High-Dose Intravenous Immunoglobulin in Skin Autoimmune Disease
por: Hoffmann, Jochen H. O., et al.
Publicado: (2019)

Therapeutic Potential of Intravenous Immunoglobulin in Acute Brain Injury
por: Thom, Vivien, et al.
Publicado: (2017)

Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2017)

Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy
por: Wasserman, Richard L., et al.
Publicado: (2017)

Intravenous Immunoglobulin and Immunomodulation of B-Cell – in vitro and in vivo Effects
por: Mitrevski, Milica, et al.
Publicado: (2015)

Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation
por: Mimura, Yusuke, et al.
Publicado: (2022)

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2016)

Cytokine dysregulation despite immunoglobulin replacement therapy in common variable immunodeficiency (CVID)
por: Poto, Remo, et al.
Publicado: (2023)

Erratum: Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation
Publicado: (2022)

Efficacy and safety of human intravenous immunoglobulin 5% (Ig VENA) in pediatric patients affected by primary immunodeficiency
por: Ricci, Silvia, et al.
Publicado: (2020)

Recombinant Human C1 Esterase Inhibitor for the Management of Adverse Events Related to Intravenous Immunoglobulin Infusion in Patients With Common Variable Immunodeficiency or Polyneuropathy: A Pilot Open-Label Study
por: Melamed, Isaac R., et al.
Publicado: (2021)

Serum Free Immunoglobulins Light Chains: A Common Feature of Common Variable Immunodeficiency?
por: Guevara-Hoyer, Kissy, et al.
Publicado: (2020)

Endothelial Cell Amplification of Regulatory T Cells Is Differentially Modified by Immunosuppressors and Intravenous Immunoglobulin
por: Lion, Julien, et al.
Publicado: (2017)

A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion
por: Kato, Hidefumi, et al.
Publicado: (2021)

Aseptic meningitis following intravenous immunoglobulin therapy of common variable immunodeficiency
por: Kaarthigeyan, K., et al.
Publicado: (2011)

Aseptic meningitis following intravenous immunoglobulin therapy of common variable immunodeficiency
por: Bhatt, Girish Chandra, et al.
Publicado: (2012)

Does Intravenous Immunoglobulin Therapy Prolong Immunodeficiency in Transient Hypogammaglobulinemia of Infancy?
por: Memmedova, Lale, et al.
Publicado: (2013)

Timing of infections in patients with primary immunodeficiencies treated with intravenous immunoglobulin (IVIg)
por: Gill, Parwinder K., et al.
Publicado: (2018)

Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study
por: Borte, Michael, et al.
Publicado: (2017)

What Is the Burden of Immunoglobulin Replacement Therapy in Adult Patients With Primary Immunodeficiencies? A Systematic Review
por: Jones, Georgina L., et al.
Publicado: (2018)

Induction of Regulatory T Cells by Intravenous Immunoglobulin: A Bridge between Adaptive and Innate Immunity
por: Kaufman, Gabriel N., et al.
Publicado: (2015)

The Ability of Zika virus Intravenous Immunoglobulin to Protect From or Enhance Zika Virus Disease
por: Pinto, Amelia K., et al.
Publicado: (2021)

Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins
por: Wang, Shang-shang, et al.
Publicado: (2023)

Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study
por: Cornblath, David R., et al.
Publicado: (2023)

Emerging Insights on Caspases in COVID-19 Pathogenesis, Sequelae, and Directed Therapies
por: Premeaux, Thomas A., et al.
Publicado: (2022)

Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients
por: Schroeder, H. W., et al.
Publicado: (2012)

Case Report: Rheumatoid meningitis with positive NMDAR antibody: A case treated with intravenous immunoglobulin
por: Zhang, Honglian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_idoaclfiqba1j0jgkjf2p78jot